Stargardt Disease

Stargardt disease image
Color photo and auto fluorescent fundus image of Stargardt disease

What is Stargardt disease?

Stargardt disease is an inherited problem of the retina. The retina is a thin layer of delicate nerve tissue that lines the inside wall of the eye like the film in a camera. In the eye, light is focused onto the retina, which “takes the picture” and sends the image to the brain. Stargardt’s disease mainly affects the central part of the retina that normally provides sharp, central, reading vision and color vision.

What causes Stargardt disease?

Stargardt disease is usually inherited in a recessive pattern, which means it may skip many generations. An individual usually inherits the affected gene from both parents who carry the gene in order to have symptoms of the condition. Individuals who have inherited the gene from only one parent usually do not exhibit symptoms and are called “carriers”. If both parents carry the gene, then one in four children will have symptoms of Stargardt disease. If a person with Stargardt disease has children with someone who does not carry the gene, none of their children will have Stargardt disease, but half of their children will carry the gene. The gene variants that cause Stargardt disease are very common; they are present in about one in twenty people.

What are the symptoms of Stargardt disease?

Stargardt disease may cause no symptoms in the early stages. It may cause symptoms early or late in life. With time, symptoms may include the following:

  1. Photophobia—unusual sensitivity to light.
  2. Hemeralopia—difficulty seeing well in bright light.
  3. Decreased color vision.
  4. Blurring of central vision, sometimes with distortion or blind spots.

If Stargardt disease progresses over many years, it may cause a loss of vision to the point of legal blindness. In such cases, the loss of central vision interferes with the ability to read and drive, but the side-vision usually remains good. Sometimes it progresses very slowly and never causes significant visual loss. The rate of visual loss can be predicted by identifying others in the same family who also have Stargardt disease, as the pattern is often similar among family members. The visual symptoms may be monitored with the Amsler grid test.

How is Stargardt disease diagnosed?

The symptoms listed above may be the first clue to the diagnosis. A routine dilated eye examination can detect the retinal changes of Stargardt disease. In most cases a fluorescein angiogram is helpful. In this procedure the ophthalmologist injects a dye into the vein of the arm and photographs are taken of the retina, which show specific changes in the retina to make the diagnosis. A free genetic test can be ordered by my office and mailed to you.  It involves a painless swab of the lining of the mouth.  It is very reliable to detect the gene that causes Stargardt disease.

How is Stargardt disease treated?

There is no proven treatment for Stargardt disease, but studies are underway to find a treatment to slow the loss of vision. Researchers recommend avoiding excessive exposure to sunlight and avoid taking vitamin A supplements. It may also be helpful to avoid excessive dietary intake of foods that contain vitamin A, such as carrots and liver.

If significant loss of vision does occur, there are programs and devices that focus on helping a person find ways to cope with the visual impairment. Various low-vision optical devices such as magnifying devices, closed-circuit televisions, and large-print reading material can help to minimize the effects of visual impairment. Your ophthalmologist can prescribe optical devices or refer you to a low-vision specialist. Because side vision is less commonly affected, the remaining sight can be very useful.

A wide range of support services, rehabilitation programs, and devices are available to help people with cone dystrophy continue with many of their favorite activities. The Lighthouse for the Blind and the Pinellas Center for the Visually Impaired have classes and specialists in providing prescription lenses to magnify printed material. The Division of Blind Services provides rehabilitation services and financial aid for eye care in selected cases. Your doctor can give free access to the “talking book” library to make “books on tape” available. A form is available from your doctor that establishes legal blindness to be used for property tax and income tax deductions. As always, if you have any questions please do not hesitate to contact your doctor for more information.

By Scott E. Pautler, MD

For a telemedicine consultation with Dr Pautler, please send email request to spautler@rvaf.com. We accept Medicare and most insurances in Florida. Please include contact information (including phone number) in the email. We are unable to provide consultation for those living outside the state of Florida.

Copyright © 2016-2022 Designs Unlimited of Florida. All Rights Reserved.

Alkeus study for treatment of Stargardt disease

There is currently no proven treatment for Stargardt disease (SD), an inherited eye condition that affects the retina and causes a slow loss of central vision over years. It affects about one in 10,000 people and may begin to cause symptoms early or late in life.

In Stardardt disease there is an abnormal protein that is involved with transporting vitamin A. In normal eyes Rim protein transports vitamin A from the retina to cells that recycle it for continued use. The retina requires vitamin A to process light for functional vision. Eyes with Stargardt disease have a defective Rim protein. As a result, vitamin A that has been used by the retina tends to accumulate in the retina in the form of toxic byproducts called vitamin A dimers (pronounced, “DYE-mer”). Vitamin A dimers are thought to contribute to permanent retinal damage over time.

Alkeus is a company that is researching the use of a drug that may slow the loss of vision in Stargardt disease. This pill (ALK-001) is taken by mouth once a day. In laboratory studies it appears to slow the formation of vitamin A dimers. It has been studied in the laboratory and now has been cleared by the FDA for study in humans. The study will compare the effect of ALK-001 to placebo (sugar pills) to determine the effectiveness and safety. Eligible patients are healthy individuals between 12 and 60 years of age. Candidates must undergo genetic testing to confirm the diagnosis. The study will last for 24months. If this and other studies prove the usefulness of ALK-001 it will likely be approved by the FDA for general use by ophthalmologists outside of clinical trials in the future.

UPDATE OCT 2022: The TEASE 1 Study reported very favorable results at the American Academy of Ophthalmology meeting in Chicago this month. There was slowing of the rate of vision loss and no prominent safety issues.

For further information and to find the study sites see: Clinical Trials

By Scott E. Pautler, MD

For a telemedicine consultation with Dr Pautler, please send email request to spautler@rvaf.com. We accept Medicare and most insurances in Florida. Please include contact information (including phone number) in the email. We are unable to provide consultation for those living outside the state of Florida.

Copyright © 2016-2022  Designs Unlimited of Florida